Trials / Conditions / Stage III Adult T-cell Leukemia/Lymphoma

Stage III Adult T-cell Leukemia/Lymphoma

22 registered clinical trials studyying Stage III Adult T-cell Leukemia/Lymphoma.

Status	Trial	Sponsor	Phase
Completed	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477	Case Comprehensive Cancer Center	EARLY_Phase 1
Terminated	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037	Northwestern University	Phase 1 / Phase 2
Completed	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015	City of Hope Medical Center	Phase 1
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Completed	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274	National Cancer Institute (NCI)	Phase 1
Completed	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193	Amir Mortazavi	Phase 1
Terminated	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745	University of Nebraska	Phase 2
Completed	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00769288	National Cancer Institute (NCI)	Phase 1
Completed	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811	National Cancer Institute (NCI)	Phase 1
Completed	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203	Fred Hutchinson Cancer Center	Phase 2
Completed	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00293345	National Cancer Institute (NCI)	Phase 1
Terminated	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid NCT00354185	National Cancer Institute (NCI)	Phase 1
Completed	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985	National Cancer Institute (NCI)	Phase 1
Terminated	Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00096005	National Cancer Institute (NCI)	Phase 1
Completed	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas NCT00089271	National Cancer Institute (NCI)	Phase 1
Completed	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011	Fred Hutchinson Cancer Center	Phase 2
Completed	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504	Fred Hutchinson Cancer Center	Phase 2
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A
Completed	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma NCT00003970	National Cancer Institute (NCI)	Phase 1